Express Pharma

USP workshop to examine ways to improve medicines quality in Asia-Pacific region

Workshop to be held in Hyderabad from May 26-28, 2015

The US Pharmacopeial Convention (USP) is bringing together national medicines control laboratory officials for a workshop on May 26-28 in Hyderabad at USP–India on improving aspects of medicines quality in the Asia-Pacific region.

At the workshop, members of the USP Global Health Impact Program’s Network of Official Medicines Control Laboratories (NOMCoL) Asia-Pacific chapter will learn new and practical analytical techniques, share best practices and discuss ways to sustainably strengthen the capacity of official medicines control laboratories in the region.

The workshop will focus on best practices for establishing and maintaining international accreditation; comprehensive methods for analysing the quality of drug samples; novel strategies and tools for increased data transparency and information sharing with laboratories, regulatory authorities and other national and international agencies and techniques to increase laboratory performance and improve drug analyses.

Invited speakers and guests include Dr PV Appaji, Director General, Pharmaceutical Export Promotions Council (Pharmexcil), PBN Prasad, Deputy Drug Controller General of India, Central Drugs Standard Control Organization (CDSCO), OS Sadhwani, Joint Commissioner, Maharashtra Food and Drug Administration (FDA) and HG Koshia, Commissioner, Gujarat FDA.

USP provides this annual workshop as a platform for NOMCoL Asia-Pacific member countries to resolve shared challenges, report on national advances, and exchange data, insights and lessons learned. By facilitating active collaboration and information-sharing across nations and regions, USP aims to advance the sustainable development of official medicines control laboratories (OMCLs) that are capable of producing and sharing harmonised and internationally-recognised data, ensuring the quality of medicines, and combating the proliferation of falsified and substandard drugs.

Comments are closed.